Literature DB >> 33540765

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.

Taku Fujimura1, Ryo Amagai1, Yumi Kambayashi1, Setsuya Aiba1.   

Abstract

Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

Entities:  

Keywords:  CTCL; HDAC inhibitors; bexarotene; interferon; targeted therapy; topical formulation

Year:  2021        PMID： 33540765      PMCID： PMC7913115          DOI： 10.3390/pharmaceutics13020200

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN： 1999-4923            Impact factor:   6.321


  80 in total

1.  Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Ann G Martin; Elise A Olsen; David P Fivenson; H Miles Prince
Journal:  Leuk Lymphoma       Date:  2012-09-03

2.  Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.

Authors:  Debra Breneman; Madeleine Duvic; Timothy Kuzel; Richard Yocum; Joseph Truglia; Victor J Stevens
Journal:  Arch Dermatol       Date:  2002-03

Review 3.  The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.

Authors:  Natalie Spaccarelli; Alain H Rook
Journal:  Dermatol Clin       Date:  2015-08-20       Impact factor: 3.478

4.  Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.

Authors:  Agustin Aviles; Natividad Neri; Jorge Fernandez-Diez; Luis Silva; Maria-Jesùs Nambo
Journal:  Hematology       Date:  2015-01-16       Impact factor: 2.269

5.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Authors:  H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic
Journal:  Lancet       Date:  2017-06-07       Impact factor: 79.321

6.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

Authors:  M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

7.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316

8.  Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.

Authors:  Stephen K Richardson; Sarah B Newton; Tami L Bach; Jeanne B Budgin; Bernice M Benoit; Julie H Lin; Jessica S Yoon; Maria Wysocka; Charles S Abrams; Alain H Rook
Journal:  Am J Hematol       Date:  2007-09       Impact factor: 10.047

9.  Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.

Authors:  Kentaro Ohuchi; Taku Fujimura; Chunbing Lyu; Ryo Amagai; Yusuke Muto; Setsuya Aiba
Journal:  Dermatol Ther       Date:  2020-08-17       Impact factor: 2.851

10.  Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.

Authors:  Taku Fujimura; Kayo Tanita; Yota Sato; Yumi Kambayashi; Sadanori Furudate; Akira Tsukada; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-01-16
View more
  3 in total

Review 1.  Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.

Authors:  Taku Fujimura
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

2.  Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene.

Authors:  Hiromu Chiba; Yumi Kambayashi; Kentaro Ohuchi; Ryo Amagai; Erika Tamabuchi; Akira Hashimoto; Taku Fujimura
Journal:  Case Rep Oncol       Date:  2022-02-01

3.  Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox.

Authors:  Mayuko Amagai; Sadanori Furudate; Kentaro Ohuchi; Toshiya Takahashi; Emi Yamazaki; Hiromu Chiba; Yoshihide Asano; Taku Fujimura
Journal:  Case Rep Oncol       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.